Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE The differences in f/t PSA, PV, and PSAD for patients with and without PCa were statistically significant.(p < .001). 30862227

2020

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 GeneticVariation BEFREE We identified 6.509 patients with prostate cancer who had received hormonal therapy with a post-hormonal therapy PSA ≥2ng/mL, 363 of whom had non-metastatic, castrate-resistant prostate cancer. 31851457

2020

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE Predictive factors of prostate cancer diagnosis with PSA 4.0-10.0 ng/ml in a multi-ethnic Asian population, Malaysia. 30962017

2020

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE Risk-based patient selection for systematic biopsy in prostate cancer diagnosis has been adopted in daily clinical practice, either by clinical judgment and PSA testing, or using multivariate risk prediction tools. 31399825

2020

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE The resulting area under the receiver operating characteristic curve (AUC) to predict csPCa was 0.76 for PI-RADS v2, 0.59 for age, and 0.67 for PSA density. 31690449

2020

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE The aim of the present study was to design and evaluate the value of prostate-specific membrane antigen (PSA)-targeted manganese oxide-mesoporous silica nanoparticles (Mn-Msns) for the detection of prostate cancer. 31731188

2020

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE In this case report, a 67-year-old male with a history of prostate cancer status post prostatectomy presented for an F-18-fluciclovine PET/CT for a rising, clinically detectable PSA and indeterminate pelvic lymph nodes seen on multiparametric MRI of the prostate. 31715513

2020

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE PSA alone does not appear to be sufficient to detect the persistence of residual prostate cancer after radiotherapy. 31628565

2020

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression BEFREE Moreover, among 143 patients with PCa who received radical prostatectomy (RP), the AUCs of LDN-PSA, LDN-PSAD, and PSAD levels (0.750, 0.812, and 0.769, respectively) detected in patients with a pathologic Gleason grade group ≥ 2 were significantly higher (P = .0170, P = .0028, and P = .0003, respectively) than that of PSA (0.578). 31711843

2020

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE Seminal citrate is superior to PSA for detecting clinically significant prostate cancer. 31808398

2020

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4-10 ng ml<sup>-1</sup>). 31169140

2020

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 GeneticVariation BEFREE In both groups there was a curative intention to treat localized high-risk prostate cancer (one or more of Gleason score 8-10, PSA 20-50 or stage T3), diagnosed between 1995-2010, follow-up at the end of 2014. 30990112

2020

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE Among subjects in a clinical trial with a prior negative biopsy, total PSA, free-PSA ratio and PSA density have comparable diagnostic characteristics for PCa screening in low and normal testosterone men. 31733275

2020

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE Seven hundred three (n = 703) prostate cancer (PCa) patients with confirmed PSA failure after radical therapy were enrolled. 31492993

2020

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE This is a prospective, multicenter clinical trial of PSMA-HBED PET/CT imaging in patients with early biochemical relapse of prostate carcinoma (median prostate-specific antigen [PSA], 2.55 ng/mL) after definitive prostatectomy (152 patients) or radiation therapy (86 patients) with either no lesions or oligometastatic disease on abdominopelvic CT and bone scan (BS). 30890448

2019

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE The prospective, multicenter LOCATE (F Fluciclovine [FACBC] PET/CT in Patients with Rising PSA after Initial Prostate Cancer Treatment) trial assessed the impact of positron emission tomography/computerized tomography with F-fluciclovine on treatment plans in patients with biochemical recurrence of prostate cancer after primary therapy with curative intent. 30179618

2019

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE Prostate cancer tumor oxygenation value was positively correlated with Gleason score (r=0.349, P<0.05) or PSA (r=0.432, P<0.05). 30950457

2019

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE Our data suggest, that SRT administered at early PSA rise might be equieffective to postoperative ART in patients with locally advanced PC. 31711524

2019

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression BEFREE This was a retrospective single tertiary institution cohort study of consecutive men between July 2014 and June 2018 who received a <sup>68</sup>Ga-PSMA PET/CT for elevated PSA levels following radiotherapy as primary treatment of prostate cancer. 31363165

2019

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression BEFREE After adjustment for tumor stage, Gleason grade, and PSA level at diagnosis, diabetic fasting glucose level after PCa diagnosis was associated with elevated risk of PCa death compared to normoglycemic men (HR 1.67 95% CI 1.18-2.36). 30679762

2019

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression BEFREE In the original publication of the article, the categories of PSA levels among the subpopulation of men diagnosed with prostate cancer were published incorrectly in Table 4. 30506128

2019

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression BEFREE In the present study, we reported that miR‑505‑3p was significantly downregulated in bone metastatic PCa tissues compared with that in non‑bone metastatic PCa tissues, but there was no significant difference in miR‑505‑3p expression between PCa and adjacent normal tissues. miR‑505‑3p expression was inversely associated with serum PSA levels, Gleason grade, N and M classification, and short bone metastasis‑free survival in PCa patients, but had no effect on overall survival in PCa patients. 30365141

2019

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE There were no significant differences between the groups in prostate cancer detection rates after stratification according to PSA density and clinical staging. 31178436

2019

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression BEFREE We first profiled global serum miRNAs in a pilot set of PCa and benign prostatic hyperplasia (BPH) cases undergoing TRUS-guided prostate biopsy due to elevated PSA levels. 31534967

2019

Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression BEFREE High PSA level, and GLUT-1 expression and lower VEGF and nuclear hTERT expression may indicate the great role of hypoxia in BR induction in PCa. 30989489

2019